Central Nervous System News and Research

RSS

Seventh Annual Neuro-Oncology Symposium to be held at Hackensack University Medical Center

The John Theurer Cancer Center at Hackensack University Medical Center will host the Seventh Annual Neuro-Oncology Symposium on Friday, May 20 from 7:30am - 1:00pm. This continuing medical education conference will present the latest neuro-oncology trends by leaders in the field.

10 May 2011

Scientists reveal nerve cells' navigation system

Johns Hopkins scientists have discovered how two closely related proteins guide projections from nerve cells with exquisite accuracy, alternately attracting and repelling these axons as they navigate the most miniscule and frenetic niches of the nervous system to make remarkably precise connections.

9 May 2011

Heptares, Shire sign deal to develop novel A2A antagonist for CNS disease treatment

Heptares Therapeutics today announced it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2A antagonist discovered by Heptares and currently in preclinical development.

9 May 2011

Elan Drug Technologies, Alkermes merge to form new company in Ireland

Alkermes, Inc. and Elan Corporation, plc today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies, the profitable, world-class drug formulation and manufacturing business unit of Elan, in a cash and stock transaction currently valued at approximately $960 million.

9 May 2011

Mithridion's MCD-386CR receives Orphan Drug designation from FDA for PSP treatment

Mithridion, Inc., a privately-owned clinical stage drug development company focusing on serious Central Nervous System disorders, announces that the U.S. Food and Drug Administration has awarded Orphan Drug designation for MCD-386CR, its lead drug candidate, for the treatment of Progressive Supranuclear Palsy.

9 May 2011

Novel neurotransmitter could fight against neurological diseases

A team of scientists has discovered that D-aspartic acid is a novel neurotransmitter that could potentially be used in the fight against neurological diseases such as Parkinson's and schizophrenia.

6 May 2011

New technique can reveal fat distribution in healthy human brain

Mapping the fat distribution of the healthy human brain is a key step in understanding neurological diseases, in general, and the neurodegeneration that accompanies Alzheimer's disease in particular. Antonio Veloso and colleagues, from the University of the Basque Country in Leioa, Spain, find a new technique to reveal the fat distribution of three different areas of the healthy human brain.

5 May 2011

New research sheds light on origins of cryptococcal fungal infection

New research has shed light on the origins of a fungal infection which is one of the major causes of death from AIDS-related illnesses. The study, published today in the journal PLoS Pathogens, funded by the Wellcome Trust and the BBSRC, shows how the more virulent forms of Cryptococcus neoformans evolved and spread out of Africa and into Asia.

4 May 2011

Hebei Aoxing Pharma receives Chinese patent for naloxone sublingual film

Aoxing Pharmaceutical, a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, announced that its operating subsidiary in China, Hebei Aoxing Pharmaceutical Group Company, has been granted a patent by the State Intellectual Property Office of The People's Republic of China for naloxone sublingual film.

3 May 2011

Teva signs definitive agreement to acquire Cephalon shares for $6.8 billion

Teva Pharmaceutical Industries Ltd. and Cephalon, Inc. today announced that their Boards of Directors have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction is not conditioned on financing and is expected to be completed in the third quarter of 2011.

2 May 2011

Abnormal connections created by central nervous system linked to persistence of chronic pain

Chronic pain is an epidemic. One in four Americans suffers from chronic pain due to disease—including cancer and HIV—and the medications used to treat those diseases. One reason for the persistence of chronic pain may be that the patient's central nervous system creates abnormal connections or improves connections that shouldn't be strengthened, explains Susan G. Dorsey, PhD, RN, co-director of the School of Nursing's Center of Excellence in Disorders of Neuroregulatory Function.

30 Apr 2011

Three hundred neurosurgeons to participate in Central Park softball tournament

With summer just around the corner, that means the Annual Neurosurgery Charity Softball Tournament will take place in Central Park for the eighth consecutive year.

30 Apr 2011

AACN to honor 22 nurses nationwide with 2011 Circle of Excellence Award

The American Association of Critical-Care Nurses will bestow the 2011 Circle of Excellence Award on 22 nurses nationwide at the National Teaching Institute & Critical Care Exposition, Chicago, April 30-May 5.

30 Apr 2011

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.

30 Apr 2011

AACN to present Flame of Excellence Award to Baylor cardiovascular nurse specialist

The American Association of Critical-Care Nurses will present the Flame of Excellence Award to Barbara "Bobbi" Leeper, RN, MN, CNS M-S, CCRN, FAHA, cardiovascular clinical nurse specialist at Baylor University Medical Center, Dallas.

30 Apr 2011

Nautic Partners announces acquisition of Omnicare Clinical Research

Nautic Partners LLC, a private equity firm with more than $2.5 billion of capital under management, today announced that it has acquired Omnicare Clinical Research from Omnicare, Inc. Headquartered in King of Prussia, PA, Omnicare CR is a full-service, global clinical research organization.

28 Apr 2011

Scientists weaken long-term memory

Could veterans of war, rape victims and other people who have seen horrific crimes someday have the traumatic memories that haunt them weakened in their brains? In a new study, UCLA life scientists report a discovery that may make the reduction of such memories a reality.

28 Apr 2011

Study finds gender difference in immune responses to PTSD

Men and women had starkly different immune system responses to chronic post-traumatic stress disorder, with men showing no response and women showing a strong response, in two studies by researchers at the San Francisco VA Medical Center and the University of California, San Francisco.

27 Apr 2011

GM-CSF appears to be key culprit in multiple sclerosis onset

Reporting in Nature Immunology, Jefferson neuroscientists have identified a driving force behind autoimmune diseases such as multiple sclerosis, and suggest that blocking this cell-signaling molecule is the first step in developing new treatments to eradicate these diseases.

25 Apr 2011

Cephalon files definitive Consent Revocation Statement, recommends shareholders to reject Valeant's proposals

Cephalon, Inc. today announced that it has filed a definitive Consent Revocation Statement with the Securities and Exchange Commission (SEC) urging shareholders to reject Valeant Pharmaceuticals International Inc.'s proposals to remove Cephalon's entire Board of Directors and replace them with nominees hand-picked by Valeant.

22 Apr 2011